GSK
$47.18Change from previous close: −2.06%Absolute change: −$0.99
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $94.53B
- Enterprise value
- $109.24B
- P/E (trailing 12 months)
- 15.5
- Forward P/E
- 9.40
- PEG
- 5.85
- Price/book
- 4.05
- Price/sales
- 2.85
- EV/EBITDA
- 10.1
- EV/revenue
- 3.29
Profitability and growth
- Gross margin
- 73.5%
- Operating margin
- 30.9%
- Net margin
- 14.5%
- ROE
- 33.4%
- ROA
- 10.0%
- Revenue growth (year over year)
- 5.3%
- Earnings growth (year over year)
- -69.5%
Financial health
- Total cash
- $3.11B
- Total debt
- $18.29B
- Debt/equity
- 1.06
- Current ratio
- 0.82
- Quick ratio
- 0.52
Dividends
- Annual dividend per share
- $1.82
- Dividend yield
- 3.9%
- Payout ratio
- 56.8%
- Ex-dividend date
- August 14, 2026
Analysts and estimates
- Average price target
- $59.58
- Median price target
- $59.00
- High price target
- $70.00
- Low price target
- $50.00
- Analysts with a price target
- 8
- Consensus
- Hold
- Forward EPS
- $5.02
- EPS estimate, current year
- $4.80
Shares and trading
- Beta
- 0.29
- Average volume
- 3.59M
- Shares outstanding
- 2B
- Float
- 1.94B
- Institutional ownership
- 17.5%
- Insider ownership
- 0.1%
- Short interest (% of float)
- 0.7%
- Short ratio (days)
- 5.33